Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of “Moderate Buy” from Analysts

Schrödinger, Inc. (NASDAQ:SDGR) has earned an average rating of “Moderate Buy” from the eleven analysts that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $32.90.

A number of research analysts have recently commented on SDGR shares. BMO Capital Markets increased their price objective on Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Morgan Stanley decreased their target price on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 21st.

Insider Activity at Schrödinger

In other Schrödinger news, insider Margaret Dugan sold 1,531 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total value of $27,221.18. Following the sale, the insider now directly owns 13,469 shares in the company, valued at $239,478.82. This trade represents a 10.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Schrödinger

A number of institutional investors have recently added to or reduced their stakes in SDGR. Nisa Investment Advisors LLC raised its holdings in Schrödinger by 145.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock valued at $27,000 after acquiring an additional 837 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Schrödinger by 49.5% in the second quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after purchasing an additional 703 shares in the last quarter. KBC Group NV lifted its position in Schrödinger by 45.4% in the third quarter. KBC Group NV now owns 2,508 shares of the company’s stock worth $47,000 after purchasing an additional 783 shares during the period. Quarry LP boosted its stake in Schrödinger by 1,150.0% during the third quarter. Quarry LP now owns 2,825 shares of the company’s stock worth $52,000 after buying an additional 2,599 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in Schrödinger in the 2nd quarter valued at $66,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Schrödinger Stock Performance

Shares of SDGR opened at $22.01 on Friday. The firm has a market cap of $1.60 billion, a PE ratio of -9.41 and a beta of 1.50. The firm’s 50 day moving average price is $18.76 and its 200 day moving average price is $20.18. Schrödinger has a twelve month low of $16.67 and a twelve month high of $38.00.

Schrödinger (NASDAQ:SDGR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.12). The business had revenue of $35.30 million during the quarter, compared to analyst estimates of $41.25 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The firm’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.86) EPS. On average, sell-side analysts anticipate that Schrödinger will post -2.29 earnings per share for the current fiscal year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.